CClinicalTrials.gg
RecruitingNCT07698366Updated Sep 28, 2026

Breast Ultrasound Screening in Elderly Women: A Multicenter Cluster Randomized Trial

An interventional study of Standardized Breast Ultrasound Screening in Breast Neoplasms and Early Detection of Cancer, sponsored by The First Affiliated Hospital with Nanjing Medical University. Recruiting at 2 sites in China. Open to female participants aged 65 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by The First Affiliated Hospital with Nanjing Medical University · Not applicable, Interventional, and Screening

Phase
Not applicable
Study type
Interventional
Enrollment
80,000
Allocation
Randomized
Ages
65 Years to 80 Years
Sex
Female
01

Study summary

This multicenter, cluster randomized trial will evaluate whether community-based breast ultrasound screening improves the early detection of breast cancer in women aged 65 to 80 years, compared with routine health management. Approximately 80,000 women in Jiangsu Province, China, will be enrolled and followed for breast cancer outcomes.

Read the detailed description

This is a multicenter, open-label, cluster randomized controlled trial in Jiangsu Province, China. Approximately 80,000 women aged 65 to 80 years will be enrolled. Participating community health service stations will be assigned to either active breast ultrasound screening or routine health management. Women in the screening group will receive a standardized breast ultrasound examination, while those in the control group will receive no additional study-specific breast screening. The primary outcome is the difference between groups in the proportion of diagnosed breast cancers that are stage I or II during 24 months of follow-up. The study will also assess other screening-related and implementation outcomes.

02

Conditions studied

  • Breast Neoplasms
  • Early Detection of Cancer

Browse trials for

03

Who can participate

Ages eligible
65 Years to 80 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Female participants aged 65-80 years.
  • Local residents living in participating communities for ≥6 months.
  • Signed informed consent and willingness to participate.

Exclusion criteria

Exclusion Criteria:

  • History of breast cancer or previous breast cancer treatment.
  • Breast cancer screening within the past 2 years.
  • Severe comorbid conditions that may affect study participation or follow-up.
  • Acute breast disease or conditions requiring immediate treatment.
  • Unable to cooperate with screening procedures due to physical or cognitive limitations.
04

Study design

Phase
Not applicable
Primary purpose
Screening
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
80,000 participants (estimated)

Study arms

  • Experimental
    Ultrasound Active Screening Group

    Participants assigned to this group through their community health service station receive one standardized breast ultrasound examination performed by a qualified physician. Abnormal findings are managed according to routine clinical practice.

    Diagnostic Test: Standardized Breast Ultrasound Screening

  • No intervention
    Routine Health Management Group

    Participants receive conventional community health management and annual physical examination according to local routine practice, without study-specific breast ultrasound screening.

Interventions

  • Diagnostic testStandardized Breast Ultrasound Screening

    One standardized breast ultrasound examination performed and interpreted by a qualified physician, with further clinical evaluation of abnormal findings as appropriate.

05

What researchers measure

Primary outcomes

  1. Absolute difference in early-stage breast cancer diagnosis rate

    The between-group absolute difference in the proportion of pathologically confirmed breast cancer cases diagnosed at stage I or II.

    Time frame: 24 months after enrollment

Secondary outcomes

  1. Overall breast cancer detection rate

    The proportion of participants diagnosed with breast cancer in each group during follow-up.

    Time frame: 24 months

  2. Late-stage breast cancer diagnosis rate

    The proportion of participants diagnosed with stage III or IV breast cancer in each group.

    Time frame: Up to 24 months after enrollment

  3. Breast biopsy rate

    The proportion of participants undergoing a breast biopsy in each group during follow-up.

    Time frame: Up to 24 months after enrollment

06

Study locations

1 of 2 sites recruiting
  • Kunshan First People's Hospital
    Kunshan, Jiangsu, China
    Recruiting
  • The Fourth Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu, China
    Not yet recruiting
07

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared because there is currently no approved data sharing policy for this multicenter study. De-identified participant data will be managed in accordance with institutional regulations and applicable ethical and legal requirements.

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07698366
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Responsible party
Sponsor
First posted
Jul 13, 2026
Start date
Sep 20, 2026
Primary completion
Sep 20, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Sep 28, 2026

Study contacts

Ge Ma, doctor
Contact
ntmage@sina.com
+8618262632870

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion